2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.04E.08 Rapid in House Next Generation Sequencing and Impact on Treatment Decisions and Initiation in Advanced NSCLC

EP.04E.08 Rapid in House Next Generation Sequencing and Impact on Treatment Decisions and Initiation in Advanced NSCLC

Pdf Summary

This study, led by Ravnoor Kang at William Osler Health System in Canada, investigates the impact of rapid in-house next-generation sequencing (NGS) on treatment decisions and initiation for patients with advanced non-small cell lung cancer (NSCLC). NGS has enhanced the identification of actionable genetic alterations in NSCLC, but in many Canadian regions, the average turnaround time (TAT) for such results is 2 weeks. The research aimed to compare the TAT for in-house NGS versus external labs and its influence on treatment decisions.<br /><br />The study utilized a retrospective analysis of NSCLC patients who underwent NGS at the health system between January 2019 and December 2022. The TAT was defined from the date of biopsy or surgery to when results were accessible in the electronic medical records. Statistical analysis (t-test) evaluated the time to treatment decision and access to targeted therapies based on the availability of NGS results at the first medical oncology consultation (FMOC).<br /><br />Findings showed that having NGS results available at the FMOC significantly increased the likelihood of making a treatment decision during that visit. Patients at William Osler Health System had NGS results available to their medical oncologists about 6 days earlier than those treated at facilities without in-house NGS. While the expected time between consultation and treatment initiation was shorter for patients with upfront NGS results, it was not statistically significant, likely due to the small sample size.<br /><br />The study concludes that community-based in-house NGS testing can greatly reduce TAT for advanced NSCLC patients, potentially improving treatment timelines. Future research is suggested to explore the broader impacts on patient outcomes and cost-effectiveness.

Asset Subtitle

Ravnoor Kang

Meta Tag

Speaker Ravnoor Kang

Topic Screening and Early Detection

Keywords

next-generation sequencing

NGS

non-small cell lung cancer

NSCLC

treatment decisions

turnaround time

William Osler Health System

in-house testing

genetic alterations

patient outcomes